Henry H. Hsu

机构：Bellevue College · ORCID：0009-0002-8018-2651

发表论文 97 篇 · 总被引 5050 次 · h-index 25

代表论文

• Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial (2019 · The Lancet · 被引 497)
• Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors (2020 · Cancer · 被引 72)
• A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia (2020 · Blood Advances · 被引 48)
• Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT (2021 · Clinical Cancer Research · 被引 32)
• Cardioprotection by the adiponectin receptor agonist ALY688 in a preclinical mouse model of heart failure with reduced ejection fraction (HFrEF) (2024 · Biomedicine & Pharmacotherapy · 被引 18)
• The slow-release adiponectin analog ALY688-SR modifies early-stage disease development in the D2.mdx mouse model of Duchenne muscular dystrophy (2023 · American Journal of Physiology-Cell Physiology · 被引 16)